KALTF - Kalytera Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
0
0
0
-
0
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
0
Operating Expenses
Research Development
8,848
7,750
1,674
1,622
-
Selling General and Administrative
3,834
3,352
3,242
3,451
92
Total Operating Expenses
-12,556
4,588
4,916
5,073
92
Operating Income or Loss
12,556
-4,588
-4,916
-5,073
-92
Interest Expense
-
153
54
-
-
Total Other Income/Expenses Net
-26,103
11,692
-17,921
-6,294
-7
Income Before Tax
-13,937
6,836
-31,863
-11,554
-98
Income Tax Expense
-5,161
-99
0
0
-
Income from Continuing Operations
-8,776
6,935
-31,863
-11,554
-98
Net Income
-8,776
6,935
-31,863
-11,554
-98
Net Income available to common shareholders
-8,776
6,935
-31,863
-11,554
-98
Reported EPS
Basic
-
0.04
-0.26
-0.90
-0.05
Diluted
-
0.01
-0.26
-0.90
-0.05
Weighted average shares outstanding
Basic
-
195,508
124,136
12,786
2,177
Diluted
-
218,343
124,136
12,786
2,177
EBITDA
-
6,989
-31,809
-5,054
-92